We are developing muscle biology-directed potential medicines to improve the healthspan of people with devastating diseases of impaired muscle function
and conditions of muscle weakness
associated with aging.
Baseline Characteristics and Demographics from FORTITUDE-ALS Similar to Other Recent Large Trials in ALS SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 29 th International Symposium on...READ MORE ›
People fighting amyotrophic lateral sclerosis have few treatment options; we are dedicated to changing the progression of this fatal disease.
Heart failure death and disability rates continue to rise, despite current treatment options. With Amgen, we are developing a novel therapy that may improve cardiac performance in people with heart failure.
People suffering from spinal muscular atrophy experience devastating loss of muscle function. With Astellas, we are working on a treatment that may enhance skeletal muscle performance in these and other patients.